Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of -7.67% is 85% above its 5-year average of -52.68%, near the high end of its 5-year range (-4393.79%–28.61%).
24.66% above its 12-month average of -10.18%.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): -10.67%.
NET PROFIT MARGIN
-7.67%
NET PROFIT MARGIN AVG TTM
-10.18%
NET PROFIT MARGIN AVG 3Y
-34.31%
NET PROFIT MARGIN AVG 5Y
-52.68%
NET PROFIT MARGIN AVG 10Y
N/A
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+24.66%
CURRENT VS 3Y AVG
+77.64%
CURRENT VS 5Y AVG
+85.44%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-0.26%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
-2850.00%
vs the sector median at left
Tarsus Pharmaceuticals, Inc.
Market Cap
$3.19B
Net Profit Margin
-7.67%
TTM Avg
-10.18%
3Y Avg
-34.31%
5Y Avg
-52.68%
Market Cap
$3.12B
Net Profit Margin
0.00%
TTM Avg
-172.68%
3Y Avg
-306.20%
5Y Avg
-1288.24%
Market Cap
$3.31B
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$3.06B
Net Profit Margin
-14191.20%
TTM Avg
0.00%
3Y Avg
-86.13%
5Y Avg
-153.41%
Market Cap
$3.03B
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$3.36B
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$3.38B
Net Profit Margin
33.42%
TTM Avg
30.07%
3Y Avg
2.48%
5Y Avg
-14.75%
Market Cap
$2.99B
Net Profit Margin
6.15%
TTM Avg
-37.77%
3Y Avg
-2241.27%
5Y Avg
-1494.18%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | $3.19B | -7.67% | -10.18% | -34.31% | -52.68% |
| Amylyx Pharmaceuticals, Inc. (AMLX)vs › | $3.12B | 0.00% | -172.68% | -306.20% | -1288.24% |
| CareDx, Inc (CDNA)vs › | $3.30B | 24.23% | 5.06% | -20.39% | -16.94% |
| Viking Therapeutics, Inc. (VKTX)vs › | $3.31B | 0.00% | 0.00% | 0.00% | 0.00% |
| Denali Therapeutics Inc. (DNLI)vs › | $3.06B | -14191.20% | 0.00% | -86.13% | -153.41% |
| Enliven Therapeutics, Inc. (ELVN)vs › | $3.03B | 0.00% | 0.00% | 0.00% | 0.00% |
| Parabilis Medicines, Inc. (PBLS)vs › | $3.36B | 0.00% | 0.00% | 0.00% | 0.00% |
| Acadia Pharmaceuticals Inc. (ACAD)vs › | $3.38B | 33.42% | 30.07% | 2.48% | -14.75% |
| Arcutis Biotherapeutics, Inc. (ARQT)vs › | $2.99B | 6.15% | -37.77% | -2241.27% | -1494.18% |
| Pulse Biosciences, Inc. (PLSE)vs › | $3.44B | -6755.78% | -10397.28% | -7288.11% | -5606.97% |
Operating Margin
-8.0%
Net Profit Margin
-7.7%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | -10.67% |
| 2026-03-31 | -4.30% |
| 2025-12-31 | -5.52% |
| 2025-09-30 | -10.60% |
| 2025-06-30 | -19.81% |
| 2025-03-31 | -32.07% |
| 2024-12-31 | -34.80% |
| 2024-09-30 | -48.67% |
| 2024-06-30 | -81.57% |
| 2024-03-31 | -129.39% |
| 2023-12-31 | -320.45% |
| 2023-09-30 | -2092.36% |
| 2023-06-30 | 0.00% |
| 2023-03-31 | -936.76% |
| 2022-12-31 | -135.99% |
| 2022-09-30 | 0.00% |
| 2022-06-30 | -37.59% |
| 2022-03-31 | -3754.73% |
| 2021-12-31 | -4393.79% |
| 2021-09-30 | -1265.89% |
| 2021-06-30 | 28.61% |
| 2021-03-31 | 30.77% |
| 2020-12-31 | 0.00% |
| 2020-09-30 | 0.00% |
| 2020-06-30 | 0.00% |
| 2020-03-31 | 0.00% |
| 2019-12-31 | 0.00% |
| 2019-09-30 | 0.00% |
| 2018-06-30 | 0.00% |
| 2018-03-31 | 0.00% |
